Skip to main content
Premium Trial:

Request an Annual Quote

Eksigent, Crelab Instruments, Imperial College London, MDS, Molecular Devices, Biozentrum, GeneBio, Power3

Eksigent Inks Distribution Deal with Crelab
Crelab Instruments will handle the sales and services of Eksigent’s NanoLC HPLC product line in Sweden and Denmark under a distribution agreement reached by the two companies announced this week.
Financial details of the agreement were not disclosed. Crelab, based in Sweden, specializes in automation, and chromatography sales and support.

ImperialCollege Chooses Dyversity
Imperial College London will use Syngene’s Dyversity 2D gel imaging system for the identification of complex proteins associated with disease, Syngene announced last week.
Scientists at Imperial College’s Institute of Biomedical Engineering will use the system to do multiplex imaging of 2D proteins pre-labeled by Cy dyes, imaging of 1D protein and DNA gels, and chemiluminescent blots stained with a range of visible, fluorescent, and chemiluminescent dyes.

MDS Purchase of Molecular Devices Approaching Finish Line
MDS said this week it has accepted 92 percent of outstanding shares of Molecular Devices, moving the acquisition of Molecular Devices closer to completion. MDS has initiated an offering period for the remaining shares of Molecular Devices, it said.
Upon completion of the acquisition, which MDS said will close “as soon as practical,” a new business unit, MDS Analytical Technologies, will be launched combining Molecular Devices with MDS Sciex.
Andy Boorn, currently MDS Sciex’s president, will lead the new unit.

Biozentrum, GeneBio Ink Deal for Phenyx
The Biozentrum of the University of Basel will integrate GeneBio’s Phenyx software platform for MS data analysis into its multi-tiered proteomics cluster under a collaboration announced this week.
The Biozentrum will use Phenyx as its primary search engine, the company and university said in a joint statement. Terms of the deal were not disclosed.     
Phenyx is a software platform for the identification and characterization of protein and peptides from MS data. The Biozentrum is a department at the University of Basel covering biochemistry, biophysical chemistry, microbiology, and other disciplines.

Power3 Taps into Noble’s Knowledge
Power3 Medical Products said last week it has hired Noble International Investment Services and its Noble Financial Group of Boca Raton, Fla., for financial advisory and investment banking services.
Noble will help Power prepare a memorandum describing the company’s business and advise the company on marketing strategies, said Steven Rash, Power3’s CEO and chairman, in a statement. Noble will also seek out possible mergers and acquisition opportunities, strategic alliances, and partnerships for Power3.

No More EnzoLyte, It’s Now Called SensoLyte
AnaSpec said last week it has changed the name of its high-performance assay kits to SensoLyte from EnzoLyte. The SensoLyte line includes kits for the screening of protein kinases, protein phosphatases, matrix metalloproteinases, renin inhibitors, HCV and HIV proteases, and caspases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.